Showing results (81-90 of 94) with videos related to
Sort By:
Pageof 10
Cancer Discovery|March 9, 2016
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic TransformationShannon Elf, Nouran S Abdelfattah, Edwin Chen, et al.Leukemia & Lymphoma|May 19, 2020
Venetoclax is safe and efficacious in relapsed/refractory AMLChezi Ganzel, Ron Ram, Alexander Gural, et al.British Journal of Haematology|May 23, 2024
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemiaEitan Kugler, Inbar Cohen, Irina Amitai, et al.Blood Advances|December 5, 2024
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort studyOfir Wolach, Itai Levi, Boaz Nachmias, et al.European Journal of Haematology|May 23, 2018
Targeted next generation sequencing for the diagnosis of patients with rare congenital anemiasNoa Shefer Averbuch, Orna Steinberg-Shemer, Orly Dgany, et al.Journal of Clinical Medicine|September 28, 2023
MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin LevelYael Haring, Noa Goldschmidt, Shaimaa Taha, et al.Blood Advances|January 26, 2022
Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapyJurjen Versluis, Manu Pandey, Yael Flamand, et al.Blood|June 21, 2024
Genotype-phenotype correlations in chronic granulomatous disease: insights from a large national cohortBaruch Wolach, Ronit Gavrieli, Ofir Wolach, et al.Blood Advances|October 30, 2023
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 studyJessica K Altman, Tsila Zuckerman, Jamie Koprivnikar, et al.Science Translational Medicine|April 13, 2018
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasmsOfir Wolach, Rob S Sellar, Kimberly Martinod, et al.Pageof 10